Drug-to-antibody determination for an antibody-drug-conjugate utilizing cathepsin B digestion coupled with reversed-phase high-pressure liquid chromatography analysis
A cathepsin B enzymatic method for cleaving the drug from ADC molecules is proposed. The method employs a cleavage/reduction of the mAb prior to cathepsin B treatment. Superior cathepsin B cleavage is obtained compared to currently published literature. The method is useful for determining DAR in ADCs with a cathepsin B cleavable linker.